Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial

By Rizkallah Élie   Stip Emmanuel   Zhornitsky Simon   Pampoulova Tania   Gendron Alain   Rompré Pierre-Paul   Chiasson Jean-Pierre   Potvin Stéphane  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 2947-2951

Informa Healthcare

Access to resources Recommend Favorite

Comparison of the Effects of Ossein-Hydroxyapatite Complex and Calcium Carbonate on Bone Metabolism in Women with Senile Osteoporosis: A Randomized, Open-Label, Parallel-Group, Controlled, Prospective Study

By Ciria-Recasens Manel  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 817-824

Adis International

Access to resources Recommend Favorite

Mirtazapine, venlafaxine effective in somatoform disorder

By  

Inpharma, Vol. 1, Iss. 1634, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers: A Randomized, Open-Label, Two-Period, Parallel-Group, Crossover Study

By Nichols Alice I.  

Clinical Drug Investigation, Vol. 31, Iss. 3, 2011-03 ,pp. : 155-167

Adis International

Access to resources Recommend Favorite

Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects: Two Prospective, Multicentre, Open-Label, Parallel-Group Volunteer Studies

By Abel Samantha  

Clinical Drug Investigation, Vol. 28, Iss. 7, 2008-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite